IL136425A - Transformed hydrolyzed thiazolidinedione, its preparation process and pharmaceutical preparations containing it - Google Patents

Transformed hydrolyzed thiazolidinedione, its preparation process and pharmaceutical preparations containing it

Info

Publication number
IL136425A
IL136425A IL13642598A IL13642598A IL136425A IL 136425 A IL136425 A IL 136425A IL 13642598 A IL13642598 A IL 13642598A IL 13642598 A IL13642598 A IL 13642598A IL 136425 A IL136425 A IL 136425A
Authority
IL
Israel
Prior art keywords
hydrate
hydrate according
provides
diabetes mellitus
prophylaxis
Prior art date
Application number
IL13642598A
Other languages
English (en)
Hebrew (he)
Other versions
IL136425A0 (en
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to IL16084798A priority Critical patent/IL160847A0/xx
Publication of IL136425A0 publication Critical patent/IL136425A0/xx
Publication of IL136425A publication Critical patent/IL136425A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13642598A 1997-12-16 1998-12-14 Transformed hydrolyzed thiazolidinedione, its preparation process and pharmaceutical preparations containing it IL136425A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL16084798A IL160847A0 (en) 1997-12-16 1998-12-14 A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726563.1A GB9726563D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical
PCT/EP1998/008153 WO1999031093A1 (en) 1997-12-16 1998-12-14 Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use

Publications (2)

Publication Number Publication Date
IL136425A0 IL136425A0 (en) 2001-06-14
IL136425A true IL136425A (en) 2004-08-31

Family

ID=10823691

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16084798A IL160847A0 (en) 1997-12-16 1998-12-14 A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same
IL13642598A IL136425A (en) 1997-12-16 1998-12-14 Transformed hydrolyzed thiazolidinedione, its preparation process and pharmaceutical preparations containing it

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL16084798A IL160847A0 (en) 1997-12-16 1998-12-14 A hydrate of substituted thiazolidinedione derivative, process for its preparation and pharmaceutical composition comprising the same

Country Status (37)

Country Link
US (4) US20020133016A1 (hu)
EP (1) EP1042321A1 (hu)
JP (1) JP2002508371A (hu)
KR (1) KR100549141B1 (hu)
CN (3) CN1285831A (hu)
AP (1) AP1363A (hu)
AR (2) AR016161A1 (hu)
AU (2) AU2272299A (hu)
BG (1) BG64850B1 (hu)
BR (1) BR9813598A (hu)
CA (1) CA2314967A1 (hu)
CO (1) CO4990943A1 (hu)
CZ (1) CZ300081B6 (hu)
DZ (1) DZ2679A1 (hu)
EA (1) EA002833B1 (hu)
EG (1) EG22250A (hu)
GB (1) GB9726563D0 (hu)
HR (1) HRP20000404A2 (hu)
HU (1) HUP0102292A3 (hu)
ID (1) ID24714A (hu)
IL (2) IL160847A0 (hu)
MA (1) MA26581A1 (hu)
MY (1) MY128573A (hu)
NO (1) NO317255B1 (hu)
NZ (1) NZ504703A (hu)
OA (1) OA11900A (hu)
PE (1) PE20000125A1 (hu)
PL (1) PL341213A1 (hu)
RS (1) RS50080B (hu)
SA (1) SA99200200B1 (hu)
SK (1) SK286422B6 (hu)
TR (2) TR200001793T2 (hu)
TW (1) TW487709B (hu)
UA (1) UA66821C2 (hu)
UY (2) UY25306A1 (hu)
WO (1) WO1999031093A1 (hu)
ZA (1) ZA9811504B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
HUP0200929A3 (en) * 1999-04-23 2004-03-29 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CO5170419A1 (es) * 1999-04-23 2002-06-27 Smithkline Beecham Plc Nuevo compuesto antidiabetico con base en sales del acido maleico
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
JP2004509961A (ja) 2000-09-26 2004-04-02 ドクター・レディーズ・リサーチ・ファウンデーション ５−［４−［２−［ｎ−メチル−ｎ−（２−ピリジル）アミノ］エトキシ］ベンジル］チアゾリジン−２，４−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法

Also Published As

Publication number Publication date
EG22250A (en) 2002-11-30
SA99200200B1 (ar) 2006-11-11
GB9726563D0 (en) 1998-02-11
AR016161A1 (es) 2001-06-20
TR199802624A3 (tr) 1999-10-21
PE20000125A1 (es) 2000-03-03
CN101318956A (zh) 2008-12-10
DZ2679A1 (fr) 2003-03-29
JP2002508371A (ja) 2002-03-19
HRP20000404A2 (en) 2000-12-31
CZ300081B6 (cs) 2009-01-28
AR017211A1 (es) 2001-08-22
KR20010033140A (ko) 2001-04-25
OA11900A (en) 2006-04-10
WO1999031093A1 (en) 1999-06-24
AU2272299A (en) 1999-07-05
ID24714A (id) 2000-08-03
CA2314967A1 (en) 1999-06-24
EA200000656A1 (ru) 2000-12-25
BG104606A (en) 2001-02-28
CN1285831A (zh) 2001-02-28
BG64850B1 (bg) 2006-06-30
US20050288513A1 (en) 2005-12-29
HUP0102292A3 (en) 2003-12-29
BR9813598A (pt) 2000-10-10
YU36400A (sh) 2003-12-31
UY25309A1 (es) 1999-07-19
AU770818B2 (en) 2004-03-04
US20030139604A1 (en) 2003-07-24
EP1042321A1 (en) 2000-10-11
IL136425A0 (en) 2001-06-14
US20070037859A1 (en) 2007-02-15
CZ20002206A3 (cs) 2000-12-13
IL160847A0 (en) 2004-08-31
CN101318957A (zh) 2008-12-10
UA66821C2 (uk) 2004-06-15
MA26581A1 (fr) 2004-12-20
AU2753802A (en) 2002-05-16
TR199802624A2 (xx) 1999-10-21
MY128573A (en) 2007-02-28
PL341213A1 (en) 2001-03-26
NZ504703A (en) 2002-12-20
RS50080B (sr) 2009-01-22
CO4990943A1 (es) 2000-12-26
NO20003070L (no) 2000-06-15
EA002833B1 (ru) 2002-10-31
NO20003070D0 (no) 2000-06-15
AP1363A (en) 2005-01-21
TW487709B (en) 2002-05-21
ZA9811504B (en) 2000-06-15
NO317255B1 (no) 2004-09-27
HUP0102292A2 (hu) 2002-05-29
SK9182000A3 (en) 2000-12-11
TR200001793T2 (tr) 2000-10-23
UY25306A1 (es) 2000-12-29
US7368574B2 (en) 2008-05-06
AP2000001829A0 (en) 2000-06-30
SK286422B6 (sk) 2008-09-05
US20020133016A1 (en) 2002-09-19
KR100549141B1 (ko) 2006-02-03

Similar Documents

Publication Publication Date Title
US7368574B2 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
US20070203200A1 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical
US20060189659A1 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt
EP1173434B1 (en) Thiazolidinedione derivative and its use as antidiabetic
EP1661895A1 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,maleic acid salt,hydrate as pharmaceutical
EP1277753A1 (en) Thiazolidinedione derivative and its use as antidiabetic
US6664278B2 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US7358366B2 (en) Thiazolidinedione derivative and its use as antidiabetic
AU774613B2 (en) Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
AU770817B2 (en) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
ZA200108722B (en) Thiazolidinedione derivative and its use as antidiabetic.